How the CHEK2 protein helps glioma tumors evade the immune system
The Immunosuppressive Function of Checkpoint Kinase 2 in Gliomas
This research looks at whether blocking the protein CHEK2 can help immune cells better recognize and kill glioma (brain tumor) cells to improve treatment for people with glioblastoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11194369 on NIH RePORTER |
What this research studies
From a patient perspective, researchers found that the CHEK2 protein helps glioma cells avoid being killed by CD8 immune cells and are now following up on why that happens. They will map how CHEK2 interacts with other tumor proteins (YBX1 and YBX3) and how those interactions change gene activity using techniques like chromatin profiling. The team will also test whether blocking CHEK2 activates immune pathways such as STING and whether CHEK2-blocking drugs that can cross the blood-brain barrier work with existing PD-1/PD-L1 immunotherapies in lab and animal models. Parts of the work use tumor tissue outside the body, and the long-term goal is to inform new combination treatments for people with glioma.
Who could benefit from this research
Good fit: Ideal candidates for related patient activities would be people with glioma who can donate tumor tissue for research or who may enroll in future clinical trials testing CHEK2 inhibitors combined with immunotherapy.
Not a fit: People without glioma or whose tumors lack the relevant CHEK2/YBX pathway activity are unlikely to benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this could lead to treatments that make immunotherapy work better for people with glioblastoma.
How similar studies have performed: Preclinical experiments reported by the team showed that inhibiting CHEK2 together with PD-1 pathway blockade improved survival in animal glioma models, but this approach has not yet been proven in patients.
Where this research is happening
Chicago, United States
- Northwestern University — Chicago, United States (Active)
Researchers
- Principal investigator: Dmello, Crismita Clement — Northwestern University
- Study coordinator: Dmello, Crismita Clement
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.